Character Biosciences has secured $93 million in Series B funding to support two lead programmes aimed at treating age-related macular degeneration, a major cause of vision loss for people over 60. The firm uses artificial intelligence to maximise clinical trial data’s value and will start phase 1 testing for both programmes later this year.
M&S issues update as crippling nationwide IT outage still ongoing – The Sun
Marks & Spencer (M&S) halted online orders in the UK and Ireland following a cyber attack, leading to a 5% drop in share price. Physical
